Huperzine A (Shuangyiping): A promising drug for Alzheimer's disease

Acta Pharmacologica Sinica

Volumn 17, Issue 6, 1996, Pages 481-484

  Tang, Xi Can ^a  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

acetylcholine; Alzheimer's disease; cholinesterase inhibitory; cognition disorders; huperzine A; memory; pharmacokinetics; physostigmine; Shuangyiping; tacrine

Indexed keywords

ACETYLCHOLINE; CHOLINESTERASE; CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; HUPERZINE A; PHYSOSTIGMINE; RADIOISOTOPE; TACRINE;

ALZHEIMER DISEASE; ANIMAL MODEL; BLOOD BRAIN BARRIER; CENTRAL NERVOUS SYSTEM; CHINESE HERB; CHOLINERGIC SYSTEM; CHOLINESTERASE INHIBITION; CLINICAL TRIAL; COGNITION; DOSE TIME EFFECT RELATION; DRUG BIOAVAILABILITY; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; LEARNING; LIVER TOXICITY; MEMORY; NONHUMAN; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; REVIEW;

ALZHEIMER DISEASE; ANIMALS; CHOLINESTERASE INHIBITORS; HUMANS; LEARNING; MEMORY; SESQUITERPENES;

EID: 0029806325     PISSN: 02539756     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (41)

1. Coyle JT, Price DL, Delong MR. Alzheimer's disease: a disorder of cortical cholinergic innervation. Science 1983; 219: 1184 - 90.
2. Giacobini E. The second generation of cholinesterase inhibitors: pharmacological aspects. In: Becker R, Giacobini K, editors. Cholinergic Basis for Alzheimer Therapy. Boston: Birkhauser, 1991: 247 - 62.
3. Becker R, Giacobini E. Mechanisms of cholinesterase inhibition in senile dementia of the Alzheimer type: clinical, pharmacological, and therapeutic aspects. Drug Dev Res 1988; 12: 163 - 95.
4. Giacobini E, Cuadra G. Second and third generation cholinesterase inhibitors: from preclinical studies to clinical efficacy. In: Giacobini E, Becker R, editors. Alzheimer Disease; Therapeutic Strategies. Boston: Birkhauser 1994: 155 - 71.
5. Yan XF, Lu WH, Lou WJ, Tang XC. Effects of huperzine A and B on skeletal muscle and electroencephalogram. Acta Pharmacol Sin 1987; 8: 117 - 23.
6. Hanin I, Tang XC, Kozikowski AP. Clinical and preclinical studies with huperzine. In: Becker R, Giacobini E, editors. Cholinergic Basis for Alzheimer Therapy. Boston: Birkhauser, 1991: 305 - 13.
7. Xu SS, Gao ZX, Weng Z, Du ZM, Xu WA, Yang JS, et al. Efficacy of tablet huperzine-A on memory, cognition, and behavior in Alzheimer's disease. Acta Pharmacol Sin 1995; 16: 391 - 5.
8. Liu JS, Zhu YL, Yu CM, Zhou YZ, Han YY, Wu FW, et al. The structure of huperzine A and B, two new alkaloids exhibiting marked anti-cholinesterase activity. Can J Chem 1986; 64: 837 - 9.
9. Ayer WA, Browne LM, Orszanska H. Alkaloids of Lycopodium selago, on the identity of selagine with huperzine A and the structure of a related alkaloid. Can J Chem 1989; 67: 1538 - 40.
10. Ellman GL, Courtney KD, Andres V Jr, Featherstone RM. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 1961; 7: 88 - 95.
11. Hunter AJ, Murray TK, Jones JA, Cross AJ, Green AR. The cholinergic pharmacology of tetrahydroaminoacridine in vivo and in vitro. Br J Pharmacol 1989; 98: 79 - 86.
12. Lin JH, Hu GY, Tang XC. Facilita tory effect of huperzine A on mouse neuromuscular transmission in vitro. Acta Pharmacol Sin 1996; 17: 299 - 302.
13. Tang XC, Kindel GH, Kozikowski AP, Hanin I. Comparison of the effects of natural and synthetic huperzine A on rat brain cholinergic function in vitro and in vivo. J Ethnopharmacol 1994; 44: 147 - 55.
14. Mckinney M, Miller JH, Yamada F, Tuckmantal W, Kozikowski AP. Potencies and stereoselectivities of enantiomers of huperzine A for inhibition of rat cortical acetylcholinesterase. Eur J Pharmacol 1991; 203: 303 - 5.
15. Wang YE, Yue DX, Tang XC. Anti-cholinesterase activity of huperzine A. Acta Pharmacol Sin 1986; 7: 110 - 3.
16. Tang XC, De Sarno P, Sugaya K, Giacobini E. Effect of huperzine A, a new cholinesterase inhibitor, on the central cholinergic system of the rat. J Neurosci Res 1989; 24: 276 - 85.
17. Guan LC, Chen SS, Lu WH, Tang XC. Effects of huperzine A on electroencepholography power spectrum in rabbits. Acta Pharmacol Sin 1989; 10: 496 - 500.
18. De Sarno P, Pomponi M, Giacobini E, Tang XC, Williams E. The effect of heptyl-physostigmine, a new cholinesterase inhibitor, on the central cholinergic system of the rat. Neurochem Res 1989; 14: 971 - 7.
19. Laganiere S, Corey J, Tang XC, Wulfer E, Hanin I. Acute and chronic studies with the anticholinesterase huperzine A: effect on central nervous system cholinergic parameters. Neuropharmacology 1991; 30: 763 - 8.
20. Hallak M, Giacobini E. Physostigmine, tacrine and metrifonate: effect of multiple doses on acetylcholine metabolism in the brain. Neuropharmacology 1989; 28; 199 - 206.
21. Bowen DM, Allen SJ, Benton JS, Goodhardt MJ, Haan EA, Palmer AM, et al. Biochemical assessment of serotonergic and cholinergic dysfunction and cerebral atrophy in Alzheimer's disease. J Neurochem 1983; 41: 266 - 72.
22. De Sarno P, Giacobini E, Modulation of acetylcholine release by nicotinic receptors in the rat brain. J Neurosci Res 1989; 22: 194 - 200.
23. Tang XC, Zhu XD, Lu WH. Studies on the nootropic effects of huperzine A and B: two selective AChE inhibitors. In: Giacobini E, Becker R, editors. Current Research in Alzheimer Therapy. New York: Taylor & Francis, 1988: 289 - 93.
24. Tang XC, Xiong ZQ, Qian BC, Zhou ZF, Zhang CL. Cognition improvement by oral huperzine A: A novel acetylcholinesterase inhibitor. In: Giacobini E, Becker R, editors. Alzheimer therapy : therapeutic strategies. Boston: Birkhauser, 1994: 113 - 9.
25. Vincent GP, Rumennik L, Cumin R, Martin J, Sepinwall J. The effects of huperzine A, an acetylcholinesterase inhibitor, on the enhancement of memory in mice, rats and monkeys. Neurosci Abs 1987; 13: 844.
26. Lu WH, Shou J, Tang XC. Improving effect of huperzine A on discrimination performance in aged rats and adult rats with experimental cognitive impairment. Acta Pharmacol Sin 1988; 9: 11 - 5.
27. Zhu XD, Tang XC. Improvement of impaired memory in mice by huperzine A and huperzine B. Acta Pharmacol Sin 1988; 9: 492 - 7.
28. Tang XC, Man YF, Chen XP, Zhu XD. Effects of huperzine A on learning and retrieval process of discrimination performance in rats. Acta Pharmacol Sin 1986; 7: 507 - 11.
29. 0G in animals. Acta Psychol Sin 1991; 23: 404 - 11.
30. Xiong ZQ, Tang XC. Effect of huperzine A, a novel acetylcholinesterase inhibitor, on radial maze performance in rats. Pharmacol Biochem Behav 1995; 51: 415 - 9.
31. Zhu XD, Tang XC. Facilitatory effects of huperzine A and B on learning and memory of spatial discrimination in mice. Acta Pharm Sin 1987; 22: 812 - 7.
32. Xiong ZQ, Han YF, Tang XC. Huperzine A ameliorates the spatial working memory impairments induced by AF64A. Neuro Report 1995; 6: 2221 - 4.
33. Cheng DH, Ren H, Tang XC. Huperzine A, a novel promising acetylcholinesterase inhibitor. Neuro Report 1996; 7: in press.
34. Lin JH, Hu GY, Tang XC. Comparison between huperzine A, tacrine, and E2020 on cholinergic transmission at mouse neuromuscular junction in vitro. Acta Pharmacol Sin 1997; 18: in press.
35. Zhang GB, Wang MY, Zheng JQ, Tang XC. Facilitation of cholinergic transmission by huperzine A in toad paravertebral ganglia in vitro . Acta Pharmacol Sin 1994; 15: 158 - 61.
36. Wang YK, Fang J, Lu WH, Tang XC. Pharmacokinetics of huperzine A in rats and mice. Acta Pharmacol Sin 1988; 9: 193 - 6.
37. Qian BC, Wang M, Zhou ZF, Chen K, Zhou RR, Chen GS. Pharmacokinetics of tablet huperzine A in six volunteers. Acta Pharmacol Sin 1995; 16: 396 - 8.
38. Hartvig P, Wiklund L, Aquilonius SM, Lindström B. Clinical pharmacokinetics of centrally acting cholinesterase inhibitors. In: Becker R, Giacobini E, editors. Cholinergic Basis for Alzheimer Therapy. Boston: Birkauser, 1991: 69 - 73.
39. Cheng YS, Lu CZ, Ying ZL, Ni WY, Zhang CL, Sang GW. 128 cases of myasthenia gravis treated with huperzine A. Acta Pharmacol Sin 1986; 7: 197 - 9.
40. Zhang RW, Tang XC, Han YY, Sang GW, Zhang YD, Ma YX, et al. Drug evaluation of huperzine A in the treatment of senile memory disorders. Acta Pharmacol Sin 1991; 12: 250 - 2.
41. Liu FG, Fang YS, Gao ZX, Zuo JD, Sou ML. Double-blind control treatment of huperzine A and placebo in 28 patients with Alzheimer disease. Clin Pharmacoepidemiol 1995; 4: 196 - 8.